World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
118
Citations
48751
World Ranking
4074
National Ranking
2234

Overview

Elias Jabbour is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the field of medicine, with a strong focus on hematology and related subfields including public health, environmental and occupational health, genetics, molecular biology, and oncology.

Their work concentrates on several main topics within hematologic malignancies and therapies, including:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • CAR-T Cell Therapy Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment

Jabbour has published extensively in leading hematology and oncology journals. Frequent publication venues include:

  • Blood (194 publications)
  • American Journal of Hematology (69 publications)
  • Clinical Lymphoma Myeloma & Leukemia (37 publications)
  • Cancer (36 publications)
  • Journal of Clinical Oncology (34 publications)

Recent papers associated with their research include:

  • "Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring," 2020, American Journal of Hematology
  • "International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data," 2022, Blood
  • "Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics," 2020, Nature Communications
  • "Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies," 2020, The Lancet
  • "Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials," 2023, Nature Medicine

Their frequent collaborators include:

  • Hagop M. Kantarjian
  • Farhad Ravandi
  • Tapan M. Kadia
  • Nicholas J. Short
  • Guillermo Garcia-Manero

Best Publications

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

    Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang

  • Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

    E. Jabbour;H. Kantarjian;D. Jones;M. Talpaz

  • Acute myeloid leukemia: current progress and future directions.

    Hagop Kantarjian;Tapan Kadia;Courtney DiNardo;Naval Daver

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

    Naval Daver;Guillermo Garcia-Manero;Sreyashi Basu;Prajwal C Boddu

  • Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

    Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia

  • Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

    Elias Joseph Jabbour;Hagop M. Kantarjian;Giuseppe Saglio;Juan Luis Steegmann

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

    Hagop M. Kantarjian;Susan OBrien;Elias Joseph Jabbour;Guillermo Garcia-Manero

  • Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

    Hagop M. Kantarjian;Farhad Ravandi;Susan OBrien;Jorge Cortes

  • Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

    Elias Jabbour;Hagop Kantarjian

  • Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

    Nitin Jain;Kathryn G. Roberts;Elias Jabbour;Keyur Patel

  • Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

    Jorge E Cortes;Elias Joseph Jabbour;Hagop M Kantarjian;Cheng Cameron Yin

  • BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

    Matthew S. Zabriskie;Christopher A. Eide;Christopher A. Eide;Srinivas K. Tantravahi;Nadeem A. Vellore

  • Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

    Elias Jabbour;Hagop Kantarjian

  • Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

    Nitin Jain;Audrey V. Lamb;Susan O’Brien;Farhad Ravandi

  • Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

    Jorge E. Cortes;Dan Jones;Susan O'Brien;Elias Jabbour

  • Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

    Jorge E. Cortes;Dan Jones;Susan O'Brien;Elias Jabbour

  • Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

    Elias Jabbour;Hagop M. Kantarjian;Dan Jones;Jenny Shan

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Nitin Jain
Nitin Jain The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to a wide range of allied health and administrative roles. For those looking for patient-focused professions with flexible entry routes, nursing degrees are a popular option. Many schools now make this pathway more accessible by offering programs at a nursing school without teas test requirement, eliminating a major admission barrier for aspiring nurses.

If you are interested in the organizational side of healthcare, a degree in healthcare administration can set you up for managerial positions in hospitals, clinics, and insurance companies. Many programs are now accelerated and fully online, ideal for those seeking career advancement without pausing their current work.

Registered nurses planning to become nurse practitioners can take advantage of specialized transition programs such as the adn to np bridge program, streamlining the path toward advanced clinical practice.

For those passionate about nutrition and public health, pursuing a nutritionist online degree provides a flexible route to becoming a certified nutritionist or wellness expert.

These diverse online options make it easier than ever to join the healthcare workforce or progress your career while balancing other commitments.

Best Scientists Citing Elias Jabbour

Trending Scientists

Recently Published Articles